Telehealth

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

AI is poised to revolutionize medicine, but 'hallucinations' pose a grave risk. Experts are now engineering new safeguards to ensure AI helps, not harms.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

A new medical AI, trained on vast proprietary data, is now live in a US clinic. It reasons like a physician, not a scribe, setting a new bar for trust and accuracy.

Dr. Brian Covino's top honor signals a shift in health tech, where AI doesn't replace doctors but learns from them. Can this model fix our broken system?

A digital health firm is trading millions in shares for a spot on the racetrack. A deep dive into the high-octane strategy to solve healthcare access.

New research shows 'Food is Medicine' programs thrive when paired with human coaching, offering a potent, scalable model for tackling chronic disease.

TelyRx just filled its millionth prescription, but the real story isn't the number. It's the 'operational innovation' of its cash-pay model that's disrupting healthcare.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

A landmark study validates Ceribell's AI in predicting neurological outcomes, signaling a major shift in critical care and bolstering its competitive edge.

With its new SmartBioSurface slides, Italian firm Tethis aims to solve a major lab challenge. The key? A nanotech surface that could reshape disease research.

Ottawa's first national eye care strategy isn't just about health. It's a calculated investment in economic resilience and systemic stability for an aging nation.

Digital health firm Osara Health is targeting the 'Cancer Care Cliff,' backing its new survivorship program with a validated 25:1 ROI and proven health outcomes.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Ottawa's new "AI for All" plan promises to revolutionize healthcare, but can its 'ironclad protections' keep pace with the technology it's unleashing?

As NY Tech Week buzzes with AI, a SoHo pop-up offers a glimpse into a future where work, fitness, and recovery are one seamless, data-driven loop. But at what cost?